Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Virpax Pharmaceuticals, Inc. (VRPX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.7600-0.4000 (-9.62%)
At close: 04:00PM EST
3.7700 +0.01 (+0.27%)
After hours: 07:55PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.1600
Open4.1400
Bid3.7600 x 1000
Ask3.8000 x 800
Day's Range3.7400 - 4.2138
52 Week Range3.7000 - 36.0000
Volume533,953
Avg. Volume815,638
Market Cap18.594M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Virpax Pharmaceuticals Reports 2021 Third Quarter Results and Recent Developments

    BERWYN, Pa., November 15, 2021--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced its financial results for the three and nine months ended September 30, 2021, and other recent developments.

  • Business Wire

    Virpax Advances Envelta™ Development with NCATS Under CRADA Agreement

    BERWYN, Pa., November 10, 2021--Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, today announced that the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) has awarded research and development contracts to support Good Manufacturing Practices (GMP) production of drug substance and drug product. as wel

  • GlobeNewswire

    Recro Awarded Development and Manufacturing Contract by National Institutes of Health (NIH) to Support Novel Nasal Spray Analgesic

    New $1.87 Million Task Order Falls Under Existing Parent “Drug Formulation and Manufacturing” Contract with NIHGAINESVILLE, Ga. and SAN DIEGO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has been awarded a new development and manufacturing contract by the Nati

Advertisement
Advertisement